Date: 14-Aug-2019

CStone announces first patient dosed in China with BLU-667

CStone Pharmaceuticals, on 13 August 2019, announced the dosing of the first patient in China for the Phase I registrational study of BLU-667, which was discovered by the companys partner Blueprint Medicines. This clinical trial is a part of the ongoing, global Phase I ARROW trial that is designed to evaluate the overall response rate (ORR), duration of response, pharmacokinetics, pharmacodynamics and safety of BLU-667 in patients with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumours.